Investment Rating - The report assigns a rating of "Outperform" for BeiGene, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [16]. Core Insights - BeiGene reported 2Q25 results with revenue of USD 1.32 billion, representing a year-on-year increase of 42%. The net income attributable to shareholders was USD 94 million, compared to a loss of USD 120 million in the same quarter last year, marking the second consecutive quarter of profitability in recurring operations. Management has raised the full-year revenue guidance to USD 5.0-5.3 billion from the previous guidance of USD 4.9-5.3 billion [2][6][7]. Summary by Sections Revenue Breakdown - Zanubrutinib generated revenue of USD 950 million, up 49% year-on-year and 20% quarter-on-quarter. U.S. sales accounted for USD 684 million (up 21% q-q), European sales were USD 150 million (up 30% q-q), and China sales were USD 83 million (up 3% q-q). Tislelizumab generated revenue of USD 194 million, up 22% year-on-year. Sales from Amgen-partnered products in China reached USD 130 million, up 40% year-on-year, primarily driven by growth in XGEVA [3][9]. Financial Metrics - The company achieved a gross margin of 87.5%, an increase of 2.4 percentage points year-on-year. R&D expenses were USD 530 million, up 16% year-on-year, with an R&D expense ratio of 40%, down 9 percentage points year-on-year. SG&A expenses were USD 540 million, up 21% year-on-year, with an SG&A expense ratio of 41%, down 6.9 percentage points year-on-year. Operating profit for the quarter was USD 88 million, compared to a loss of USD 107 million in 2Q24 [3][7]. Future Catalysts - Key future catalysts for BeiGene include the readout of phase II data for Sonrotoclax (BCL2) in R/R MCL and the submission of a global accelerated approval application. The company also anticipates the approval of Tislelizumab for early NSCLC in the EU and plans to initiate phase III trials for CDK4 in HR+/HER2- breast cancer in 2026 [4].

Investment Rating - The report assigns an "Outperform" rating to Yantai China Pet Foods, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [19]. Core Insights - The company's net profit attributable to the parent company for 1H25 was RMB 203 million, a year-on-year increase of 42.6%, driven by strong growth in proprietary brands and overseas factories [2][9]. - Total operating revenue for 1H25 reached RMB 2.43 billion, reflecting a 24.3% year-on-year increase, with a gross profit margin of 31.4%, up 3.4 percentage points from the previous year [2][9]. - The company has raised its guidance for certain business lines, increasing the domestic revenue growth target to 35% and the brand export target from RMB 400 million to RMB 450 million [3][10]. Summary by Sections Financial Performance - In 1H25, the company achieved total operating revenue of RMB 2.43 billion, up 24.3% year-on-year, and net profit attributable to the parent company of RMB 203 million, up 42.6% year-on-year [2][9]. - The gross profit margin for 1H25 was 31.4%, with domestic and overseas gross profit margins at 37.7% and 27.9%, respectively [2][9]. - The selling and administrative expense ratios increased to 12.2% and 8.0%, respectively, due to higher marketing investments [2][9]. Business Segments - Revenue from pet food and supplies reached RMB 2.34 billion, with pet treats, staple food, and supplies growing by 6.4%, 86%, and 11% year-on-year, respectively [3][10]. - Domestic business revenue was RMB 857 million, accounting for 35.3% of total revenue, while overseas business revenue was RMB 1.575 billion, accounting for 64.8% of total revenue [3][10]. Strategic Developments - The establishment of a new factory in Mexico aims to enhance overseas business development, with half of its capacity planned for the U.S. market [4][11]. - The company is actively engaging in diverse marketing activities and new product launches to support the growth of its proprietary brands [5][12].

Investment Rating - The report maintains an "Outperform" rating for Yum China Holdings [1][6][13] Core Insights - In 1H25, Yum China achieved revenue of USD 5.77 billion, a year-on-year increase of 2%, with adjusted net profit at USD 510 million, also up 2% [12] - For 2Q25, revenue reached USD 2.79 billion, a 4% year-on-year increase, and adjusted net profit was USD 220 million, a 1% increase; operating profit hit USD 300 million, marking a 14% growth and a new high for the second quarter [12][1] - The company is expected to continue a steady pace of store expansion, with a target of adding 1,600 to 1,800 new stores in 2025, focusing on franchise empowerment [3][6] Financial Performance Summary - Revenue projections for 2025-2027 are USD 11.74 billion, USD 12.18 billion, and USD 12.77 billion, with year-on-year growth rates of 3.9%, 3.7%, and 4.9% respectively [6][13] - Adjusted net profits for the same period are forecasted at USD 940 million, USD 1.04 billion, and USD 1.15 billion, with growth rates of 2.8%, 11%, and 10.6% respectively [6][13] - The diluted EPS is projected to be USD 2.5 in 2025, increasing to USD 3.1 by 2027 [6][11] Sales and Operational Insights - Same-store sales growth (SSSG) was positive, with overall sales growth of 4% in 2Q25; KFC and Pizza Hut saw sales growth of 5% and 3% respectively [2] - KFC's order volume remained stable with a 1% increase in average ticket price, while Pizza Hut's order volume increased by 17% but saw a 13% decrease in average ticket price due to more value-oriented offerings [2] Store Expansion and Profitability - As of the end of 1H25, Yum China operated 16,978 restaurants, with a net increase of 336 stores in 2Q25 [3] - The restaurant profit margin improved by 0.6 percentage points to 16.1% in 2Q25, attributed to reduced costs in food, packaging, and rent [3] Shareholder Returns and Digital Initiatives - Yum China returned USD 536 million to shareholders in 1H25, with plans to return USD 3 billion between 2025 and 2026 [4] - Digital orders accounted for 94% of restaurant revenue in 2Q25, with a 22% year-on-year increase in delivery sales [4]

Investment Rating - The report provides a positive outlook for AMD, indicating an outperform rating based on expected revenue growth and strong performance in key segments [19]. Core Insights - AMD reported FY2Q25 revenue of $7.69 billion, exceeding market expectations of $7.43 billion, with a Non-GAAP EPS of $0.48, aligning with consensus [6][1]. - The growth was primarily driven by strong sales of EPYC and Ryzen processors, which offset the negative impact of export controls on Instinct sales [6][1]. - The company anticipates significant revenue contributions from the MI400 series and Helios platform starting in 2026, representing a multi-billion dollar opportunity [8][3]. Revenue Breakdown - For 2Q25, revenue by segment was as follows: - Data Center revenue: $3.2 billion, up 14% YoY, with an operating loss of $155 million due to inventory costs [6][1]. - Client and Gaming revenue: $3.6 billion, up 69% YoY, with an operating profit of $767 million and an operating profit margin (OPM) of 21% [6][1]. - Embedded revenue: $824 million, down 4% YoY, with an operating profit of $257 million and an OPM of 33% [6][1]. Future Outlook - For 3Q25, AMD expects revenue between $8.4 billion and $9.0 billion, with a midpoint of $8.7 billion, representing a 28% YoY increase, primarily driven by high double-digit growth in the Data Center segment [10][4]. - The Non-GAAP gross margin is projected to be 54%, with operating expenses estimated at $2.55 billion [10][4]. AI Business Growth - AMD's AI business continues to show strong growth, particularly with the MI350 series accelerators, which have demonstrated competitive performance in training and inference workloads [7][2]. - The MI355 model has entered mass production ahead of schedule and is expected to significantly contribute to Data Center growth in the second half of the year [7][2]. Product Development - The MI400 series is on track for development, with expected AI performance reaching 40 PFLOPs and leading in memory and bandwidth metrics [8][3]. - The Helios platform, designed for complex AI tasks, is anticipated to enhance performance significantly for advanced models [8][3]. Shipment Delays - The MI308 product is currently under review by the U.S. Department of Commerce, causing delays in shipments, with limited output expected in 3Q25 [9][3].

Investment Rating - The report maintains an "OUTPERFORM" rating for the company with a target price of HKD 17.90, up from a previous target of HKD 13.40 [2][14][32]. Core Insights - The company reported a revenue of RMB 612 million for H1 2025, a 23% year-on-year increase, primarily driven by an upfront payment from Merck of USD 85 million [20][21]. - The gross profit for the same period was RMB 610 million, with net profit reaching RMB 330 million, reflecting a 59% increase year-on-year [20][21]. - The company has a robust cash position of approximately RMB 2.3 billion, which supports its operations and planned R&D investments for the next 2-3 years without the need for external financing [22][23]. Financial Performance - Revenue projections for FY25-27 are revised to RMB 610 million, RMB 630 million, and RMB 630 million respectively, with corresponding net profit estimates of RMB 30 million, RMB 130 million, and RMB 350 million [14][32]. - The company’s revenue growth is projected at 2544% for FY25, followed by 21% for FY26, and 3% for FY27 [17]. Pipeline and Product Development - The company has a well-structured pipeline, including one asset at the NDA stage and several others in various clinical phases, indicating a clear strategy for market expansion [22][24]. - Lead assets ABSK021 and ABSK011 are expected to contribute significantly to revenue within the next 2-3 years, with ABSK021 showing a 54% overall response rate in a Phase III study [24][28]. - ABSK011 has demonstrated promising results in treating liver cancer, with an overall response rate of 44.8% in second-line patients [28][29]. Strategic Direction - The management aims to expand from early-stage small molecules into bispecific antibodies, antibody-drug conjugates (ADCs), and autoimmune diseases, targeting broader market opportunities [22][23]. - The company has repurchased approximately HKD 150 million worth of shares over the past two years, reflecting a commitment to shareholder returns [23]. Valuation - The valuation is based on a risk-adjusted discounted cash flow (DCF) model, with a WACC of 10.0% and a terminal growth rate of 3.5%, leading to a target price of HKD 17.90 per share [14][32].

Investment Rating - The report provides an investment rating of "Outperform" for the company, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark by more than 10% [23]. Core Insights - In Q2 2025, the company's revenue reached $2.2 billion, exceeding expectations by $100 million, with a year-over-year growth of 30.4% [7][8]. - The non-GAAP gross margin was reported at 65.6%, surpassing previous guidance of 63%, and showing improvements from both the previous quarter and year [7][8]. - The company has raised its full-year revenue growth expectation for 2025 from 17% to 25%, with the target revenue increased from $8.2 billion to $8.75 billion, driven by growth in AI, cloud, and enterprise sectors [9][10]. Revenue and Growth - Q2 2025 revenue was $2.2 billion, a 30.4% increase year-over-year, with software and service renewals contributing approximately 16.3% [7][8]. - The company expects Q3 revenue to be around $2.25 billion [11]. Profit Metrics - Operating income in Q2 2025 surpassed $1 billion for the first time, reaching $1.08 billion, which accounted for 48.8% of revenue; net profit was $923.5 million, or 41.9% of revenue [8]. - Diluted earnings per share were reported at $0.73, reflecting a year-over-year increase of 37.7% [8]. Gross Margin and Operating Margin - The expected gross margin for 2025 is projected to be between 63% and 64%, with an operating margin of approximately 48% [10]. AI Network Business Progress - The company has positioned its AI network solutions as the preferred platform for various AI accelerators, primarily supporting NVIDIA GPUs and initiating collaborations with AMD and other startups [12]. - The back-end AI network revenue target is set at $750 million, with overall AI network revenue expected to exceed $1.5 billion by 2025 [12][13]. - The Etherlink product portfolio is noted as the most comprehensive solution in the industry, enhancing GPU utilization and reducing data exchange times by 30% to 50% [13].

Core Insights - The report highlights an escalating competition among Chinese e-commerce platforms in the instant retail and food delivery market, with significant subsidies being deployed to capture user attention and market share. This competition is not solely focused on short-term transaction volume but reflects deeper strategic goals centered around user acquisition and platform stickiness [55] - Alibaba is investing RMB 50 billion over 12 months to enhance its logistics and service integration across platforms like Taobao Flash Sale and Ele.me, aiming to improve user experience and operational efficiency [55] - Meituan, as the market leader, has achieved over 120 million daily orders, while JD.com is focusing on quality and high-frequency categories through its "Double Hundred Plan" to support brand sales and improve merchant services [55] Group 1: Competitive Strategies and Subsidy Analysis - The intense competition in the food delivery and instant retail market is driven by platforms extending their services to cover local life scenarios, with Alibaba integrating various services to enhance user retention and cross-category conversion [6][7] - The national appliance subsidy program has provided a strong boost to platforms, with JD.com benefiting the most due to its dominance in the home appliance category, while Alibaba's impact is more moderate due to its broader category coverage [17][21] - The order volume in the food delivery and instant retail market surged from approximately 100 million in May to 250 million daily orders by July, indicating a significant increase in market activity [55][29] Group 2: Market Share and Future Outlook - The report anticipates that by the end of 2025, the market share distribution among Meituan, Taobao Flash Sale & Ele.me, and JD.com will be approximately 60%:30%:10%, respectively, with future competition focusing on user retention and operational efficiency post-subsidy [35][55] - The total addressable market (TAM) for food delivery and instant retail is projected to reach approximately RMB 4.1 trillion by 2030, driven by increasing consumer acceptance of home delivery services and improvements in technology and supply chain networks [32][35] - The report emphasizes that the competition will hinge on who can maintain their core advantages through precise operations and scene-based product innovation after the subsidy war [35]

Investment Rating - The report provides a rating of "Outperform" for Infineon, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [15]. Core Insights - Infineon reported FY25 Q3 revenue of €3.7 billion, aligning with market expectations, and an EPS of €0.37, surpassing the consensus of €0.34, showcasing strong profitability resilience [1][5]. - The automotive segment (ATV) generated €1.87 billion, down 11.5% YoY, while the Power & Sensor Systems (PSS) segment saw significant growth of 40.6% YoY, reaching €1.53 billion, driven by robust demand for AI server power solutions [1][2][5]. - The company anticipates FY2025 AI-related revenue to reach €600 million, potentially increasing to €1 billion in FY2026, highlighting the substantial impact of AI on performance [2][6]. - Infineon is strategically managing inventory, with current turnover at 176 days, above the target of 120 days, but plans to reduce it to 150-160 days by fiscal year-end, reflecting a cautious yet flexible approach to market recovery [3][7]. Summary by Sections Financial Performance - Infineon's Q3 FY25 revenue was €3.7 billion, with an EPS of €0.37, exceeding market expectations [1][5]. - The adjusted gross margin improved to 43% from 40.9% in Q2 FY25, driven by increased shipments and lower idle costs [1][5]. Business Segments - Automotive (ATV) revenue was €1.87 billion, down 11.5% YoY; Green Industrial Power (GIP) revenue was €431 million, down 9.3% YoY; PSS revenue was €1.53 billion, up 40.6% YoY; Connected Secure Systems (CSS) revenue was €349 million, down 4.6% YoY [1][5]. - The PSS segment's growth is primarily attributed to strong demand for AI server power solutions, with significant collaborations, such as with NVIDIA on a high-voltage DC power architecture [2][6]. Future Outlook - For Q4 FY25, revenue is projected at €3.9 billion, reflecting a 5.3% QoQ increase but a slight decline of 0.5% YoY, with all business segments expected to grow [3][8]. - FY2025 revenue is forecasted at €14.6 billion, a decrease of 2.2% YoY, with adjusted gross margin expected to remain above 40% [3][8].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 6.05 based on a 15.5x PE for 2025 [5][9]. Core Insights - The company's wind power assets in Fujian are of high quality, and the power supply-demand situation in Fujian is favorable, indicating potential for renewable energy absorption [11]. - The current valuation shows a strong safety margin with a PB of 1.4x and a PE of 13x for 2025E, alongside expectations for asset injections, making it a long-term investment opportunity [11]. - The company experienced a decline in power generation in Q2 2025, with a total of 0.51 billion kWh generated, down 18% year-over-year, primarily due to weak wind resources [10][11]. Financial Summary - The projected financials indicate total revenue of RMB 1,732 million for 2023, with a slight increase to RMB 1,741 million in 2024, and expected growth to RMB 2,144 million by 2027 [4]. - Net profit attributable to the parent company is forecasted to decrease from RMB 678 million in 2023 to RMB 651 million in 2024, before rising to RMB 851 million by 2027 [4]. - The estimated EPS for 2025 is RMB 0.39, increasing to RMB 0.45 by 2027 [5][9]. Project Developments - The company has several projects in the pipeline, including the Chang Le offshore project with a total investment of RMB 7.3 billion, expected to contribute approximately RMB 0.5 million to annual net profit [12]. - Another project, the Chang Le B area offshore wind project, has an estimated annual net profit contribution of RMB 0.2 million [12]. - A total of 480,000 kW fishery-PV projects have been filed, with an expected annual net profit contribution of RMB 0.4 million [12].

[Table_Title] 研究报告 Research Report 5 Aug 2025 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 美国能源 US Energy 全球最大数据中心集中地电力市场 PJM 容量拍卖价格创新高 PJM Capacity Auction Price Hits Record High in the World's Largest Data Center Hub 毛琼佩 Olivia Mao 杨钰其 Yuqi Yang olivia.qp.mao@htisec.com yq.yang@htisec.com 2025 年 7 月 22 日，全球最大数据中心集中地所在电力市场 PJM 发布《2026/2027 年度容量电价拍卖报告》。PJM 拍卖清算价格统一为拍卖价格上限——329.17 美元/MW-日，再创历史新高，标志着 PJM 市场整体电力供需关系进 一步趋紧。 点评 价格再创历史新高，RTO 统一清算价达上限 PJM 的业务范围覆 ...